Vanda Pharmaceuticals, Inc. sharply criticized the US Food and Drug Administration’s “notice of opportunity for hearing” procedure while arguing that the agency must begin a hearing next month on its refusal to approve a supplemental new drug application for Hetlioz.
The agency announced in an 11 October Federal Register notice that it is proposing to refuse the application to add...








